

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

New Programs Trastuzumab Emtansine for Adjuvant Therapy of Breast Cancer (UBRAJKAD) | Neoadjuvant Carboplatin and Paclitaxel Followed by Dose-Dense AC for Triple-Negative Breast Cancer (BRLACTWACG)

Drug Update

Quinagolide Discontinuation | Daratumumab Infusion Reactions and Steroid Premedications

Provincial Pharmacy Directives

Filter Size Standardization | IV Bag Size Selection

Cancer Drug Manual[®]

New Entrectinib | **Revised** Capecitabine, Ceritinib, Fluorouracil

Benefit Drug List

New UBRAJKAD, BRLACTWACG | **Deleted** SAHDMTX

New Protocols, PPPOs and Patient Handouts

UBRAJKAD, BRLACTWACG

Revised Protocols, PPPOs and Patient Handouts

BR BRAJACT, BRAJACTG, BRAJDAC, BRAJDC, BRAJDCARBT, BRAJFEC, BRAJFEC, BRAJTDC, BRAJTR, BRAVDOC, BRAVGEMD, BRAVGEMP, UBRAVKAD, BRAVTRAD, BRAVTRAT, BRLAACD, BRLAACDT, BRLACTWAC, BRLATACG | **CN** CNBEV, CNCARV, CNCCV | **GI** GIAAVCT, GIAVCETIR, GIAVDOC, GIAVPANI, GIAVPG, GIENACTRT, UGIFFIRPAN, UGIFFOXPAN, GIFUC, GIGAVRAMT, GIPE | ... continued over ...

GO GOBEP, GOCABR, GOCABRBEV, GOCISP, GOCISPBEV, GOCXAJCAT, GOCXCAD, GOCXCAT, GOCXCATB, GOENDCAD, GOENDCAT, GOEP, GOOVBEVG, GOOVBEVLD, GOOVBEVP, GOOVBEVV, GOOVCAD, GOOVCAG, GOOVCARB, GOOVCATB, GOOVCATM, GOOVCATR, GOOVCATX, GOOVDDCAT, GOOVETO, GOOVPLDC, GOOVIPP, GOOVPLDC, GOSADG, GOSCPE, GOSCPERT, GOTDEMACO | **GU** UGUAVIPNI, GUAVNIV, GUAVNIV4, UGUAVPEM, UGUAVPEM6, GUAVPEMAX, GUAVPG, GUBEP, GUEDPM, GUEP, GUFUPRT, GUPCABA, GUPDOC, GUPDOCADT, GUPRAD, GUSCARB, GUSCPE, GUSCPERT, GUTEM, GUTIP, GUVIP2 | **HN** HNAVDOC, HNAVFUP, HNAVM, UHNAVNI, UHNAVNI4, HNAVP, HNAVPC, HNAVPD, HNAVPE, HNLALTPRT, HNLACAFRT, HNLACART, HNLACETRT, HNLACF, HNNAVFUP, HNNAVP, HNNAVPC, HNNAVPE, HNNAVPG, HNNLAPRT, HNSAVFUP, HNSAVNP | **LK** BMTLPDRIT, BMTMM0301, ULKBLIN, ULKGEMOZ, ULKINOZ | **LU** LUAJPC, LUAVDC, LUAVDOC, ULUAVNIV, ULUAVNIV4, LUAVNP, LUAVPC, ULUAVPCPMB, LUAVPG, ULUAVPGPMB, ULUAVPMB, ULUAVPMB6, ULUAVPMBF, ULUAVPMBF6, LUAVPMBM, LUAVPMBM6, LUAVPP, LUAVPPMBM, ULUAVPPMB, LULACATRT, ULULADUR, ULULADUR4, LULAPE2RT, LULAPERT, LUOTPE, LUOTPERT, LUPUPE, LUSCPE, LUSCPERT, LUSCPI | **LY** LHETCSPA, LYABVD, LYALEM, LYASPMED, LYBEND, LYBENDR, LYCHLRR, LYCHOPR, LYCHOPRMTX, LYCLLBE, LYCLLBENDR, LYCLLCHLR, LYCLLCVPR, LYCLLFBR, LYCLLFLUDR, LYCODOXMR, LYCVPPABO, LYCVPR, LYCYCLO, LYEPOCHR, LYFCR, LYFLU, LYFLUDR, LYGDPR, LYHDMRP, LYIDELAR, LYIVACR, LYNIV, LYNIV4, LYOBEND, LYPALL, LYPEM, LYPEM6, LYRICE, LYRMTN, LYSMILE, LYVENETOR, LYVIPDRT | **MY** UMYDARB, UMYDARLD | **PU** PUCAT | **SA** SAAJADIC, SAALT2W, SAALT3W, SAAVADIC, SAAVGEMD, SAAVIME3, SAAVTC, SAHDMTX, SAIME | **SC** SCMESNA | **SM** USMAJNIV, USMAJNIV4, USMAJPEM, USMAJPEM6, USMAVCEM, SMAVFIPI, SMAVIPI, USMAVIPNI, SMAVNIV, SMAVNIV4, SMAVPEM, SMAVPEM6, SMMCCPE

Resources and Contact Information

Editor's Choice

New Programs

The BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs effective 01 May 2021. The [Chemotherapy Protocols](#) section on the BC Cancer website has full details of these programs.

Breast

Trastuzumab Emtansine for Adjuvant Therapy of Breast Cancer (UBRAJKAD) — The BC Cancer Breast Tumour Group is introducing trastuzumab emtansine for select patients in the adjuvant treatment setting. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate, consists of the monoclonal antibody trastuzumab (T) and a microtubule inhibitor (DM1, which is part of the emtansine moiety). Eligibility for adjuvant T-DM1 includes HER2-positive early stage breast cancer with residual disease after preoperative, taxane-based neoadjuvant therapy. T-DM1 should start within 12 weeks of surgery. The treatment protocol provides full details for eligibility, including the need for BC Cancer Compassionate Access Program (CAP) approval.

Editor's Choice

New Programs

The phase III KATHERINE trial compared T-DM1 to trastuzumab in HER2-positive patients with early stage breast cancer with residual disease after neoadjuvant therapy.^{1,2} The 3-year rate for invasive disease-free survival (iDFS) was significantly improved in the T-DM1 group (88% vs. 77%, HR 0.50, 95% CI 0.39-0.64). Safety data were consistent with the known safety profile of T-DM1, with more grade 3 or greater adverse events (AEs) and AE-related treatment withdrawals in the T-DM1 group.

Neoadjuvant Carboplatin and Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide for Triple-Negative Breast Cancer (BRLACTWAC_G) — Currently most breast protocols with a dose-dense option [doxorubicin and cyclophosphamide (AC) delivered every 2 weeks] use a separate protocol code for their respective dose-dense option (denoted by a G). Until now, the BRLACTWAC protocol was used for all patients receiving neoadjuvant carboplatin and weekly paclitaxel followed by AC for triple-negative breast cancer, whether AC was delivered every 2 or 3 weeks. For consistency, BC Cancer is introducing the **BRLACTWAC_G** protocol for patients receiving the **dose-dense option**. Patients receiving AC every 3 weeks will continue to follow BRLACTWAC. The delivery of carboplatin and weekly paclitaxel remains the same in both protocols. BRLACTWAC has been revised to reflect the removal of the dose-dense option.

References

1. Pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC). Final recommendation for trastuzumab emtansine (Kadcyla®) for early breast cancer. 22 Jan 2020.
2. von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. *N Engl J Med* 2019;380:617-628. <https://doi.org/10.1056/NEJMoa1814017>

Drug Update

Quinagolide Discontinuation

Quinagolide is a dopamine receptor agonist used in the treatment of pituitary adenomas as part of the CNQUIN protocol. The manufacturer (Ferring Canada) is discontinuing quinagolide, and inventory is expected to be depleted by the end of April 2021. There is no alternate manufacturer.

BC Cancer Centres and Community Oncology Network (CON) sites have variable supplies remaining. For the limited number of patients currently receiving treatment with quinagolide, prescribers should confirm with their pharmacy department regarding available supply and expiry date prior to prescribing further treatment. No new patients should start on quinagolide. Once supply is no longer available, patients will need to be switched to alternate treatment options as follows:

Current Protocol	Treatment Alternatives
CNQUIN <i>Protocol to 'retire' after quinagolide supplies have been depleted</i>	CNB protocol (bromocriptine)
	CNCAB protocol (cabergoline)

Adapted from BC Cancer Briefing Note 24 April 2021

Drug Update

Daratumumab Infusion Reactions and Steroid Premedications

Half of all patients experience infusion reactions with daratumumab, most commonly with the first dose. The risk of infusion reactions is significantly reduced after the third dose; as such, the use of steroids as a premedication is not required after cycle 1. Patients on a therapeutic dose of steroids should use the therapeutic steroid dose as their premedication; however, the minimum dose of dexamethasone 20 mg (or prednisone 100 mg) is not required prior to each daratumumab infusion after the first cycle. Additionally, the 60 minute time frame for daratumumab premedications is no longer required. The daratumumab-containing protocols (UMYDARBD and UMYDARLD) have been revised to reflect these changes. As a result of these changes, and because there is no documented therapeutic benefit of dexamethasone beyond cycle 8 with UMYDARBD, dexamethasone is not required on day 1 from cycle 9 onwards with the UMYDARBD protocol.

Provincial Pharmacy Directives

Filter Size Standardization

Filters are used extensively in the preparation and administration of cancer drug products for the purpose of removing particulate matter. The 0.2 micron and 0.22 micron filters are indistinguishable, with the only difference being the designated pore size rating. As per the FDA Sterile Drug Products guidance, 0.2 micron and 0.22 micron filters are considered interchangeable.¹

In recent years, manufacturers have been standardizing filter size nomenclature and continue to revise and update product labels on an ongoing basis. Consequently, the 0.2 micron filter size has been widely adopted as the preferred nomenclature. To reflect this filter size standardization, **Provincial Pharmacy Directive III-50-04** has been updated and is available on the Shared Health Organizations Portal (SHOP) [BC Cancer page](#). The title of the directive has also been updated to reflect the scope of the directive as pertaining to both preparation and administration: **Management of Particulate during Sterile Preparation and Administration**.

BC Cancer documents are being updated with standardized filter size nomenclature as summarized below:

- Filter information in **BC Cancer protocols** and **PPPOs** and in the **BC Cancer Chemotherapy Preparation and Stability Chart** is being standardized according to the guiding principles outlined in Provincial Pharmacy Directive III-50-04
 - Where applicable, reference to a **0.2 micron in-line filter** will replace previously used filter size designations such as 0.22 micron, 0.2-1.2 micron or 0.2-5 micron
 - There is no change to the use of larger pore size filters (i.e., 15 micron in-line filter)
- **BC Cancer Drug Manual drug monographs** will continue to include all applicable filter sizes as indicated in their respective Health Canada-approved manufacturer product monographs (e.g., 0.2 micron and/or 0.22 micron, as well as larger pore size filters)

Reference

1. Food and Drug Administration. US Department of Health and Human Services. Guidance for Industry. Sterile Drug Products. Produced by Aseptic Processing – Current Good Manufacturing Practice. Rockville, MD; September 2004.
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070342.pdf>

Provincial Pharmacy Directives

IV Bag Size Selection

BC Cancer pharmacy staff are often involved in the selection of appropriate IV bag sizes for parenteral drugs with concentration-dependent stability or for drugs with large drug volumes. A new Provincial Pharmacy procedure – **IV Bag Size Selection for Drugs with Concentration-Dependent Stability or Large Drug Volume** – outlines a standardized approach for IV bag size selection in these scenarios. The procedure will soon be available on the SHOP [BC Cancer page](#).

Pertinent changes for BC Cancer staff as this procedure goes into effect include:

- **BC Cancer protocols and PPPOs** will contain suggested IV bag size(s) for the standard dose (100% dose) indicated in the protocols; minor revisions have been made to the infusion times for some drugs in order to accommodate IV bag size changes
- The **BC Cancer Chemotherapy Preparation and Stability Chart** will indicate specific dose cutoffs for IV bag sizes
- The **BC Cancer Drug Library** will adjust applicable Guardrails limits to accommodate changes in IV bag volumes and infusion times

Cancer Drug Manual[©]

All BC Cancer Drug Manual[©] documents can be accessed from the [Cancer Drug Manual[©]](#) home page on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Entrectinib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Angela Chan of the BC Cancer Lung Tumour Group. Entrectinib is a multi-target tyrosine kinase inhibitor used in the treatment of ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumours. The usual dose is 600 mg orally, given daily on a continuous basis.

Highlights from these documents include:

- fatigue, diarrhea and dizziness are frequently reported side effects
- CNS-related adverse events and cognitive disorders are common and can include dysesthesia, dysgeusia, mood disorders, memory impairment and mental status changes
- rare but serious, and sometimes fatal, side effects include pulmonary embolism, respiratory failure and tumour lysis syndrome

Entrectinib has been added to the **Auxiliary Label List** and has been evaluated for the **BC Cancer Hazardous Drug List**.

Revised Documents

Highlights of key changes are listed below:

Capecitabine Monograph and Patient Handout

Contraindications: added absence of DPD activity as a contraindication

Side Effects: added paragraph about management of diarrhea

Interactions: added allopurinol to table

Dosage Guidelines: removed dose banding/rounding table as this information has been updated and added to the applicable protocols

Patient Handout: updated management instructions to include use of loperamide (IMODIUM[®])

Ceritinib Monograph and Patient Handout

Interactions: updated esomeprazole information in table

Patient Handout: added instructions regarding antacids and H₂ blockers to Interaction bullet

Auxiliary Label List: amended to include recommendation to space antacids

Fluorouracil Monograph

Contraindications: added absence of DPD activity as a contraindication

Interactions: added allopurinol to table

Supply and Storage: updated currently available Canadian brands

Benefit Drug List

New Programs

The following new treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 May 2021:

Protocol Title	Protocol Code	Benefit Status
Adjuvant Therapy for Breast Cancer using Trastuzumab Emtansine (KADCYLA)	UBRAJKAD	Restricted
Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	BRLACTWACG	Class I

Deleted Programs

The following treatment program has been deleted from the [Benefit Drug List](#) effective 01 May 2021:

Protocol Title	Protocol Code	Benefit Status
Treatment of Osteosarcoma using High-Dose Methotrexate with Leucovorin Rescue	SAHDMTX	Deleted

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UBRAJKAD	Adjuvant Therapy for Breast Cancer using Trastuzumab Emtansine (KADCYLA)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
BRLACTWACG	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Dose-Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				
BRAJACT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
BRAJACTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Doxorubicin and Cyclophosphamide Followed by Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
BRAJDAC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, Doxorubicin and Docetaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
BRAJDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel and Cyclophosphamide	<i>IV bag size clarified</i>	----	----
BRAJDCARBT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel, Carboplatin and Trastuzumab	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
BRAJFECD	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel	<i>IV bag cutoff removed</i>	----	----
BRAJFECDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>IV bag cutoff removed</i>	----	----
BRAJTDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Trastuzumab, Docetaxel and Cyclophosphamide	<i>IV bag cutoff removed</i>	----	----

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJTR	Adjuvant Therapy for Breast Cancer using Trastuzumab Following the Completion of Chemotherapy (Sequential)	<i>Eligibility updated</i>	----	----
BRAVDOC	Palliative Therapy for Metastatic Breast Cancer using Docetaxel	<i>IV bag size clarified</i>	----	----
BRAVGEMD	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and Docetaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
BRAVGEMP	Palliative Therapy for Metastatic Breast Cancer using Cisplatin and Gemcitabine	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
UBRAVKAD	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine	<i>Eligibility and in-line filter clarified; Tests updated</i>	<i>Hypersensitivity banner added</i>	----
BRAVPTRAD	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN) and Docetaxel as First-Line Treatment for Advanced Breast Cancer	<i>IV bag cutoff removed</i>	----	----
BRAVPTRAT	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN) and Paclitaxel as First-Line Treatment for Advanced Breast Cancer	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
BRLAACD	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel	<i>IV bag cutoff removed</i>	----	----
BRLAACDT	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>IV bag cutoff removed</i>	----	----
BRLACTWAC	Neoadjuvant Therapy for Triple-Negative Breast Cancer using Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Treatment days, IV bag size and Dose Modifications clarified; Dose-dense option moved to <u>BRLACTWACG</u></i>	<i>Treatment days, lab tests and IV bag size clarified</i>	----
BRLATACG	Neoadjuvant Therapy for Breast Cancer using Dose-Dense Therapy: Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
CN Neuro-Oncology				
CNBEV	Palliative Therapy for Recurrent Malignant Gliomas using Bevacizumab with or without Concurrent Etoposide or Lomustine	<i>IV bag size, infusion time clarified</i>	<i>IV bag size clarified</i>	----
CNCARV	Carboplatin and Etoposide in the Treatment of Recurrent Ependymoma and Oligodendroglioma	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
CNCCV	Adjuvant Lomustine, Cisplatin and Vincristine in Adult High-Risk Medulloblastoma or Other Primitive Neuro-Ectodermal Tumour (PNET)	<i>Tests updated</i>	Inpatient PPPO updated	
GI Gastrointestinal				
GIAAVCT	First-Line Palliative Treatment of Metastatic Anal Squamous Cell Carcinoma using Carboplatin and Weekly Paclitaxel	<i>IV bag size clarified, IV bag cutoff removed</i>	<i>IV bag size clarified</i>	----
GIAVCETIR	Third-Line Treatment of Metastatic Colorectal Cancer using Cetuximab in Combination with Irinotecan	<i>In-line filter clarified</i>	<i>In-line filter clarified</i>	----
GIAVDOC	Palliative Treatment of Metastatic Esophagogastric Adenocarcinoma with Docetaxel	<i>IV bag size clarified</i>	----	----
GIAVPANI	Palliative Third-Line Treatment of Metastatic Colorectal Cancer using Panitumumab	<i>IV bag cutoff removed, in-line filter clarified</i>	<i>IV bag cutoff removed</i>	----
GIAVPG	First-Line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and Cisplatin	<i>CAP requirement for additional cycles removed; IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GIENACTRT	Neoadjuvant Treatment of Esophageal and Gastroesophageal Carcinomas using Carboplatin, Paclitaxel and Radiation Therapy	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
UGIFFIRPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin and Panitumumab	<i>IV bag cutoff removed, in-line filter clarified</i>	<i>IV bag cutoff removed</i>	----
UGIFFOXPAN	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Panitumumab	<i>IV bag cutoff removed</i>	<i>IV bag cutoff removed</i>	----
GIFUC	Palliative Chemotherapy for Upper Gastrointestinal Tract Cancer (Gastric, Esophageal, Gall Bladder, Pancreas Carcinoma and Cholangiocarcinoma) and Metastatic Anal using Infusional Fluorouracil and Cisplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GIGAVRAMT	Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer using Weekly Paclitaxel and Ramucirumab	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
GIPE	Palliative Therapy of Neuroendocrine Tumours using Cisplatin and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
GO Gynecologic				
GOBEP	Therapy of Ovarian Germ Cell Cancer using Bleomycin, Etoposide and Cisplatin	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOCABR	Alternative Treatment of Gynecological Malignancies using Carboplatin and Paclitaxel NAB (ABRAXANE)	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOCABRBEV	Alternative Treatment of Gynecological Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB (ABRAXANE)	<i>IV bag size, infusion time clarified</i>	<i>IV bag size clarified</i>	----
GOCISP	Alternative Treatment of Gynecological Malignancies using Cisplatin and Paclitaxel	<i>IV bag size clarified</i>	----	----
GOCISPBEV	Alternative Treatment of Gynecological Malignancies using Bevacizumab, Cisplatin and Paclitaxel	<i>IV bag size, infusion time clarified</i>	<i>IV bag size clarified</i>	----
GOCXAJCAT	Primary Adjuvant Treatment of Adenocarcinoma/ Adenosquamous Cancer of the Cervix with Carboplatin and Paclitaxel Preceding or Following Irradiation with or without Cisplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOCXCAD	Primary Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with Carboplatin and Docetaxel in Ambulatory Care Settings	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOCXCAT	Primary Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with Carboplatin and Paclitaxel in Ambulatory Care Settings	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOCXCATB	Primary Treatment of Metastatic or Recurrent Cancer of the Cervix with Bevacizumab, Carboplatin and Paclitaxel	<i>IV bag size, infusion time clarified</i>	<i>IV bag size clarified</i>	----
GOENDCAD	Treatment of Primary Advanced or Recurrent Endometrial Cancer using Carboplatin and Docetaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOENDCAT	Treatment of Primary Advanced or Recurrent Endometrial Cancer using Carboplatin and Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOEP	Therapy of Dysgerminomatous Ovarian Germ Cell Cancer using Cisplatin and Etoposide	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
GOOVBEVG	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine	<i>IV bag size, infusion time clarified</i>	----	----
GOOVBEVLD	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Doxorubicin Pegylated Liposomal	<i>IV bag cutoff removed</i>	<i>IV bag size clarified</i>	----
GOOVBEVP	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Paclitaxel	<i>IV bag size clarified</i>	----	----
GOOVBEVV	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	<i>IV bag size clarified</i>	----	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOOVCAD	Primary Treatment with Visible or No Visible Residual Tumour (Moderate, High, or Extreme Risk) or Treatment at Relapse of Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, using Carboplatin and Docetaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVCAF	Treatment of Advanced Ovarian Cancer in Patients who have Progressed or Recurred Following First-Line Platinum-Based Treatment using Carboplatin and Gemcitabine	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVCARB	First- or Second-Line Therapy for Invasive Epithelial Ovarian Cancer using Single-Agent Carboplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVCATB	Primary Treatment of Invasive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer with High Risk of Relapse using Bevacizumab, Carboplatin and Paclitaxel	<i>IV bag size, infusion time clarified</i>	<i>IV bag size clarified</i> Induction PPPO	----
GOOVCATM	Primary Treatment of No Visible Residual (Moderate-High Risk) Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer using Carboplatin and Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVCATR	Second-Line Treatment of Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Relapsing after Primary Treatment using Paclitaxel and Carboplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVCATX	Primary Treatment of Visible Residual (Extreme Risk) Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer using Carboplatin and Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVDDCAT	Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Carboplatin and Weekly Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVETO	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Etoposide	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVFPLDC	First-Line Treatment of Epithelial Ovarian Cancer using Doxorubicin Pegylated Liposomal and Carboplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVIPPC	Primary Treatment of Stage III Less Than or Equal to 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer using Intravenous and Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
GOOVPLDC	Treatment of Epithelial Ovarian Cancer Relapsing after Primary Treatment using Doxorubicin Pegylated Liposomal and Carboplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GOSADG	Treatment of Uterine Sarcoma Cancer using Docetaxel and Gemcitabine	<i>IV bag size clarified, institution name revised</i>	----	----
GOSCPPE	Treatment of Small Cell Gynecologic Cancer with Cisplatin and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
GOSCPERT	Treatment of Small Cell Gynecologic Cancer using Cisplatin and Etoposide with Radiation Therapy	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
GOTDEMACO	Therapy for High-Risk Gestational Trophoblastic Neoplasia (GTN) using Etoposide, Methotrexate, Leucovorin (Folinic Acid), Dactinomycin, Cyclophosphamide and Vincristine	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
GU Genitourinary				
UGUAVIPNI	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Ipilimumab and Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i> Induction and Maintenance PPPOs	----
GUAVNIV	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab	<i>IV bag size clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
GUAVNIV4	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab	<i>IV bag size clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
UGUAVPEM	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using Pembrolizumab	<i>Concentration range removed</i>	----	----
UGUAVPEM6	Treatment of Locally Advanced or Metastatic Urothelial Carcinoma using 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
GUAVPEMAX	Treatment of Metastatic Renal Cell Carcinoma using Pembrolizumab and Axitinib	<i>Concentration range removed</i>	----	----
GUAVPG	Palliative Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	<i>IV bag size clarified, institution name and TALLman lettering revised</i>	<i>IV bag size clarified</i>	----
GUBEP	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide and Cisplatin	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
GUEDPM	Treatment of Metastatic Adrenocortical Cancer with Etoposide, Doxorubicin, Cisplatin and Mitotane	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
GUEP	Etoposide-Cisplatin Protocol for Germ Cell Cancers	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUFUPRT	Combined Modality Therapy for Squamous Cell Cancer of the Genitourinary System using Fluorouracil and Cisplatin with Radiation	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
GUPCABA	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Cabazitaxel and Prednisone	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	-----
GUPDOC	Palliative Therapy for Metastatic Hormone-Refractory Prostate Cancer using Docetaxel and Prednisone	<i>IV bag size clarified</i>	-----	-----
GUPDOCADT	First-Line Treatment of Castration Sensitive, Metastatic Prostate Cancer using Docetaxel and Androgen Deprivation Therapy	<i>IV bag size clarified</i>	-----	-----
GUPRAD	Therapy for Metastatic Castration-Resistant Prostate Cancer using Radium-223	<i>Eligibility updated</i>	-----	-----
GUSCARB	Adjuvant Therapy for Stage I High-Risk Seminoma using Carboplatin	<i>IV bag size clarified, institution name revised</i>	<i>IV bag size clarified, institution name revised</i>	-----
GUSCPE	Palliative Therapy of Extensive Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	-----
GUSCPERT	Therapy of Genitourinary Small Cell Tumours with a Platin and Etoposide with Radiation	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	-----
GUTEM	Therapy for Advanced Renal Cancer using Temsirolimus	<i>In-line filter clarified</i>	<i>In-line filter clarified</i>	-----
GUTIP	Advanced Therapy for Relapsed Testicular Germ Cell Cancer using Paclitaxel, Ifosfamide and Cisplatin (TIP)	<i>IV bag size clarified</i>	<i>IV bag size clarified</i> Inpatient PPPO	-----
GUVIP2	Consolidation and Salvage Therapy for Nonseminoma using Etoposide, Cisplatin, Ifosfamide, Mesna	<i>IV bag size clarified</i>	<i>IV bag size clarified</i> Inpatient PPPO	-----
HN Head and Neck				
HNAVDOC	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Docetaxel	<i>IV bag size clarified, institution name revised</i>	-----	-----
HNAVFUP	Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer using Fluorouracil and Platinum	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	-----
HNAVM	Treatment of Head and Neck Cancer using Methotrexate as Standard Therapy	-----	<i>Cycle length revised</i>	-----
UHNAVIV	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	-----

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UHNAVIV4	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
HNAVP	Palliative Chemotherapy for Advanced Head and Neck Squamous Cell Carcinoma with Weekly Cisplatin	<i>IV bag size clarified, institution name revised</i>	<i>IV bag size clarified</i>	----
HNAVPC	Treatment for Unresectable, Locoregionally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck using Paclitaxel and Cisplatin or Carboplatin	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNAVPD	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Platinum and Docetaxel	<i>IV bag size clarified, institution name revised</i>	<i>IV bag size clarified</i>	----
HNAVPE	Treatment of Recurrent and Metastatic Squamous Cell Cancer with Platinum and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
HNLAALPRT	Locally Advanced (Alternate) Head and Neck Cancer using Cisplatin During Radiation Therapy	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNLACAFRT	Combined Chemotherapy (Carboplatin and Fluorouracil) and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNLACART	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Concurrent Carboplatin and Radiation	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNLACETRT	Combined Cetuximab and Radiation Treatment for Locally Advanced Squamous Cell Carcinoma of the Head and Neck	<i>In-line filter clarified</i>	<i>In-line filter clarified</i>	----
HNLADCF	Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck with Docetaxel, Cisplatin and Infusional Fluorouracil	<i>IV bag size clarified</i>	----	----
HNAVFUP	Advanced Nasopharyngeal Cancer of the Head and Neck using Platinum and Fluorouracil	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNAVP	Palliative Chemotherapy for Advanced Head and Neck Nasopharyngeal Carcinoma with Weekly Cisplatin	<i>IV bag size clarified, institution name revised</i>	<i>IV bag size clarified</i>	----
HNAVPC	Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma with Carboplatin and Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNAVPE	Treatment of Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
HNNAVPG	Treatment of Locoregionally Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Gemcitabine	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNNLAPRT	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
HNSAVFUP	Treatment of Advanced Head and Neck Cancer using Cisplatin and Fluorouracil	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
HNSAVNP	Palliative Treatment of Advanced Salivary Gland Cancers with Cisplatin and Vinorelbine	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
LK Leukemia				
BMTLPDRIT	Pre-Emptive Rituximab Therapy of Epstein-Barr Virus (EBV)-Related Post-Transplant Lymphoproliferative Disease	<i>IV bag cutoff removed, institution name revised</i>	----	----
BMTMM0301	Conditioning Therapy for Autologous Stem Cell Transplant using High-Dose Melphalan in the Treatment of Multiple Myeloma	<i>IV bag size clarified</i>	----	----
ULKBLIN	Treatment of Philadelphia Chromosome (Ph)-Positive or Ph-Negative Refractory or Relapsed Pre-B-Cell Acute Lymphoblastic Leukemia with Blinatumomab	<i>In-line filter clarified</i>	----	----
ULKGEMOZ	Treatment of Acute Myeloid Leukemia using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy	<i>IV bag size clarified</i>	----	----
ULKINOZ	Treatment of Relapsed or Refractory Pre-B Cell Acute Lymphoblastic Leukemia with Inotuzumab Ozogamicin	<i>IV bag size clarified</i>	----	----
LU Lung				
LUAJPC	Adjuvant Carboplatin and Paclitaxel Following Resection of Stage I, II and IIIA Non-Small Cell Lung Cancer	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
LUAVDC	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Docetaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
LUAVDOC	Second- or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Docetaxel	<i>IV bag size clarified</i>	----	----
ULUAVNIV	Treatment of Advanced Non-Small Cell Lung Cancer using Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
ULUAVNIV4	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
LUAVNP	Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LUAVPC	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Carboplatin and Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
ULUAVPCPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin and Pembrolizumab	<i>IV bag size clarified, concentration range removed</i>	<i>IV bag size clarified</i>	----
LUAVPG	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Gemcitabine	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
ULUAVPGPMB	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Platinum, Gemcitabine and Pembrolizumab	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
ULUAVPMB	Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	<i>Concentration range removed</i>	----	----
ULUAVPMB6	Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
ULUAVPMBF	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using Pembrolizumab	<i>Concentration range removed, in-line filter clarified</i>	----	----
ULUAVPMBF6	First-Line Treatment of Advanced Non-Small Cell Lung Cancer using 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
LUAVPMBM	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Pembrolizumab	<i>Concentration range removed</i>	----	----
LUAVPMBM6	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
LUAVPP	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
LUAVPPMBM	Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer with Pemetrexed and Pembrolizumab	<i>Concentration range removed</i>	----	----
ULUAVPPPMB	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed and Pembrolizumab	<i>IV bag size clarified, concentration range removed</i>	<i>IV bag size clarified</i>	----
LULACATRT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Carboplatin and Paclitaxel with Radiation Therapy	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----
ULULADUR	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Durvalumab	<i>Concentration range removed, in-line filter clarified</i>	<i>In-line filter clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
ULULADUR4	Treatment of Locally Advanced Non-Small Cell Lung Cancer using 4-Weekly Durvalumab	<i>Concentration range removed, in-line filter clarified</i>	<i>In-line filter clarified</i>	----
LULAPE2RT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Alternative Dosing of Cisplatin and Etoposide with Radiation Therapy	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
LULAPERT	Treatment of Locally Advanced Non-Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation Therapy	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LUOTPE	Treatment of Thymoma with Cisplatin and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LUOTPERT	Treatment of Thymoma using Cisplatin and Etoposide with Radiation Therapy	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LUPUPE	Treatment of Cancer of Unknown Primary Involving the Thorax with Cisplatin and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LUSCPE	Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Cisplatin and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LUSCPERT	Treatment of Limited Stage Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation Therapy	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LUSCPI	Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan with or without Platinum	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
LY Lymphoma				
HLHETCSPA	Treatment of Hemophagocytic Lymphohistiocytosis with Etoposide, Dexamethasone and Cyclosporine	<i>Infusion time, in-line filter clarified</i>	<i>Infusion time, in-line filter clarified</i> Week 1-2 and Week 3-8 PPPOs	----
LYABVD	Treatment of Hodgkin Lymphoma with Doxorubicin, Bleomycin, Vinblastine and Dacarbazine	<i>Hydrocortisone administration revised and moved to Premedication section</i>	<i>Hydrocortisone administration revised and moved to Premedication section; bleomycin use clarified</i>	----
LYALEM	Treatment with Subcutaneous or Intravenous Alemtuzumab for Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) or with Intravenous Alemtuzumab for Previously Untreated T-Prolymphocytic Leukemia (T-PLL)	<i>Contact information for drug distribution program updated</i>	<i>Contact information for drug distribution program updated</i>	----

REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYASPMEDX	Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma using Pegaspargase, Methotrexate and Dexamethasone	<i>Methotrexate dosing units revised to g/m²</i>	<i>Methotrexate dosing units revised to g/m²</i> Inpatient PPPO	----
LYBEND	Treatment of Non-Hodgkin Lymphoma with Bendamustine	<i>Concentration range removed</i>	----	----
LYBENDR	Treatment of Non-Hodgkin Lymphoma with Bendamustine and Rituximab	<i>Concentration range, IV bag cutoff removed</i>	----	----
LYCHLRR	Treatment of Indolent B-Cell Lymphoma with Chlorambucil and Rituximab	<i>IV bag cut off removed</i>	----	----
LYCHOPR	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (CHOP-R)	<i>IV bag cut off removed</i>	----	----
LYCHOPRMTX	Central Nervous System Prophylaxis with High-Dose Methotrexate, CHOP and Rituximab in Diffuse Large B-Cell Lymphoma	<i>IV bag cut off removed</i>	----	----
LYCLLBEND	Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) with Bendamustine	<i>Concentration range removed</i>	----	----
LYCLLBENDR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Bendamustine and Rituximab	<i>Concentration range, IV bag cutoff removed</i>	----	----
LYCLLCHLR	Treatment of Chronic Lymphocytic Leukemia with Chlorambucil and Rituximab	<i>IV bag size clarified, IV bag cutoff removed</i>	----	----
LYCLLCVPR	Treatment of Relapsed Chronic Lymphocytic Leukemia using Cyclophosphamide, Vincristine, Prednisone and Rituximab (CVP-R)	<i>IV bag cut off removed</i>	----	----
LYCLLFBR	Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) with Bendamustine and Rituximab	<i>Concentration range, IV bag cutoff removed</i>	----	----
LYCLLFLUDR	Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and Rituximab	<i>IV bag size clarified, IV bag cutoff removed</i>	<i>IV bag size clarified</i>	----
LYCODOXMR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Leucovorin (CODOX-M) and Rituximab	<i>Methotrexate dosing units revised to g/m²; IV bag size clarified</i>	<i>Methotrexate dosing units revised to g/m²</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYCVPPABO	Treatment of Hodgkin Lymphoma with Cyclophosphamide, Vinblastine, Procarbazine, Prednisone, Doxorubicin, Vincristine and Bleomycin	<i>Hydrocortisone administration revised and moved to Premedication section; infusion time and in-line filter clarified</i>	<i>Hydrocortisone administration revised and moved to Premedication section; IV bag size, infusion time and in-line filter clarified</i>	----
LYCVPR	Treatment of Advanced Indolent Lymphoma using Cyclophosphamide, Vincristine, Prednisone and Rituximab (CVP-R)	<i>IV bag cutoff removed</i>	----	----
LYCYCLO	Therapy of Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma using Cyclophosphamide	<i>IV bag cutoff clarified</i>	----	----
LYEPOCHR	Treatment of Lymphoma with Dose-Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone and Rituximab with Intrathecal Methotrexate	<i>IV bag size, in-line filter clarified</i>	----	----
LYFCR	Treatment of Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia with Fludarabine, Cyclophosphamide and Rituximab	<i>IV bag size, infusion time clarified, IV bag cutoff removed</i>	<i>IV bag size clarified</i>	----
LYFLU	Treatment of Low-Grade Lymphoma or Chronic Lymphocytic Leukemia with Fludarabine	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
LYFLUDR	Treatment of Relapsed Indolent Lymphoma with Fludarabine and Rituximab	<i>IV bag size, infusion time clarified, IV bag cutoff removed</i>	<i>IV bag size clarified</i>	----
LYGDPR	Treatment of Lymphoma with Gemcitabine, Dexamethasone and Platinum with Rituximab	<i>IV bag size clarified, IV bag cutoff removed</i>	----	----
LYHDMRP	Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and Rituximab	<i>IV bag size clarified, IV bag cutoff removed</i>	----	----
LYIDELAR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) using Idelalisib and Rituximab	<i>Concentration range, IV bag cutoff removed</i>	<i>Idelalisib dosing frequency clarified</i>	----
LYIVACR	Treatment of Burkitt Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and Rituximab	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>Infusion time, in-line filter clarified</i>	----
LYNIV	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
LYNIV4	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 4-Weekly Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYOBBEND	Treatment of Rituximab-Refractory Follicular Lymphoma (FL) with Obinutuzumab in Combination with Bendamustine	<i>Concentration range removed</i>	----	----
LYPALL	Lymphoma Palliative Chemotherapy	<i>In-line filter clarified, institution name revised</i>	----	----
LYPEM	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Pembrolizumab	<i>Concentration range removed</i>	----	----
LYPEM6	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
LYRICE	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab	<i>IV bag size, infusion time, in-line filter clarified, IV bag cutoff removed</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
LYRMTN	Maintenance Rituximab for Indolent Lymphoma	<i>IV bag size clarified</i>	----	----
LYSMILE	Treatment of Natural Killer or T-Cell Lymphoma using Dexamethasone, Methotrexate, Ifosfamide, Pegaspargase and Etoposide	<i>Methotrexate dosing units revised to g/m²; IV bag size, infusion time and in-line filter clarified</i>	<i>Methotrexate dosing units revised to g/m²; IV bag size, infusion time and in-line filter clarified</i> Inpatient PPPO	----
LYVENETOR	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Rituximab	<i>IV bag size clarified, IV bag cutoff removed</i>	----	----
LYVIPDRT	Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-Cell Lymphoma, using Concurrent Radiation and Weekly Cisplatin Followed by Etoposide, Ifosfamide, Cisplatin and Dexamethasone	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----
MY Myeloma				
UMYDARBD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone with or without Cyclophosphamide	<i>Premedications and steroids updated</i>	<i>Premedications and steroids updated</i> Cycle 1 and Cycle 2+ PPPOs	<i>Premeds and steroids updated</i>
UMYDARLD	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone	<i>Premedications and steroids updated</i>	<i>Premedications and steroids updated</i> Cycle 1 and Cycle 2+ PPPOs	<i>Premeds and steroids updated</i>
PU Primary Unknown				
PUCAT	Primary Treatment of Cancer of Unknown Primary Origin using Carboplatin and Paclitaxel	<i>IV bag size clarified</i>	<i>IV bag size clarified</i>	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SA Sarcoma				
SAAJADIC	Adjuvant Treatment of Patients with Soft Tissue Sarcoma using Doxorubicin and Dacarbazine	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
SAALT2W	Etoposide, Ifosfamide-Mesna (SAIME) Alternating with Vincristine, Doxorubicin and Cyclophosphamide (with or without Mesna) (SAVAC or SAVACM) with Filgrastim Support at <u>TWO</u> Weekly Intervals for Newly Diagnosed Ewing Sarcoma/ Ewing Family of Tumours, Desmoplastic Intra-Abdominal Small Round Blue Cell Tumour or Rhabdomyosarcoma	<i>IV bag size, infusion time, in-line filter clarified</i>	----	----
SAALT3W	Etoposide, Ifosfamide-Mesna (SAIME) Alternating with Vincristine, Doxorubicin and Cyclophosphamide (with or without Mesna) (SAVAC or SAVACM) with Filgrastim Support at <u>THREE</u> Weekly Intervals for Newly Diagnosed Ewing Sarcoma/ Ewing Family of Tumours, Desmoplastic Intra-abdominal Small Round Blue Cell tumour or Rhabdomyosarcoma	<i>IV bag size, infusion time, in-line filter clarified</i>	----	----
SAAVADIC	Treatment of Patients with Soft Tissue Sarcoma using Doxorubicin and Dacarbazine	<i>IV bag size, infusion time clarified</i>	<i>IV bag size, infusion time clarified</i>	----
SAAVGEMD	Therapy for Soft Tissue Sarcomas using Gemcitabine and Docetaxel	<i>IV bag cutoff removed</i>	<i>IV bag size clarified</i>	----
SAAVIME3	3-Day Etoposide and Ifosfamide-Mesna for Patients with Advanced Soft Tissue or Bony Sarcomas	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i> Inpatient PPPO	----
SAAVTC	Treatment of Recurrent and Refractory Neuroblastoma, Ewing's Sarcoma, Osteogenic Sarcoma or Rhabdomyosarcoma with Topotecan and Cyclophosphamide	<i>IV bag size, infusion time clarified</i>	<i>IV bag size clarified</i>	----
SAHDMTX	Treatment of Osteosarcoma using High-Dose Methotrexate with Leucovorin Rescue	<i>Discontinued</i> Removed from BC Cancer webpage	----	----
SAIME	Etoposide, Ifosfamide-Mesna (SAIME) for Use in Sarcomas	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i> Inpatient PPPO	----
SC Supportive Care				
SCMESNA	MESNA Dosage Modification for Hematuria Secondary to Oxazaphosphorines (e.g. Ifosfamide and Cyclophosphamide)	----	<i>IV bag size, infusion time and in-line filter clarified</i> SAIME/SAAVIME3 Inpatient PPPO	----

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SM Skin and Melanoma				
USMAJNIV	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
USMAJNIV4	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using 4-Weekly Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
USMAJPEM	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using Pembrolizumab	<i>Concentration range removed</i>	----	----
USMAJPEM6	Adjuvant Treatment of Resected Stage III-IV NED Melanoma using 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
USMAVCEM	Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cemiplimab	<i>Concentration range removed</i>	----	----
SMAVFIPI	First-Line Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
SMAVIPI	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
USMAVIPNI	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab and Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i> Induction and Maintenance PPPOs	----
SMAVNIV	Treatment of Unresectable or Metastatic Melanoma using Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
SMAVNIV4	Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab	<i>IV bag size, in-line filter clarified</i>	<i>IV bag size, in-line filter clarified</i>	----
SMAVPEM	Treatment of Unresectable or Metastatic Melanoma using Pembrolizumab	<i>Concentration range removed</i>	----	----
SMAVPEM6	Treatment of Unresectable or Metastatic Melanoma using 6-Weekly Pembrolizumab	<i>Concentration range removed</i>	----	----
SMMCCPE	Treatment of Recurrent or Metastatic Merkel Cell Carcinoma (MCC) with Cisplatin and Etoposide	<i>IV bag size, infusion time, in-line filter clarified</i>	<i>IV bag size, infusion time, in-line filter clarified</i>	----

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information Cancer Drug Manual Editor Pharmacy Oncology Certification Nurse Educators	604-877-6275 250-519-5500 x 693742 250-712-3900 x 686820 604-877-6000 x 672638	druginfo@bccancer.bc.ca nbadry@bccancer.bc.ca rxchemocert@bccancer.bc.ca nursinged@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Manufacturer Patient Assistance Programs: http://www.bccancer.bc.ca/mpap		
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice Professional Practice, Nursing Provincial Systemic Therapy Program	604-877-6000 x 672247 604-877-6000 x 672623 604-877-6000 x 672247	mclin@bccancer.bc.ca BCCancerPPNAdmin@ehcnet.phsa.ca mclin@bccancer.bc.ca
BC Cancer – Abbotsford BC Cancer – Kelowna BC Cancer – Prince George BC Cancer – Surrey BC Cancer – Vancouver BC Cancer – Victoria	604-851-4710 250-712-3900 250-645-7300 604-930-2098 604-877-6000 250-519-5500	toll free 877-547-3777 toll free 888-563-7773 toll free 855-775-7300 toll free 800-523-2885 toll free 800-663-3333 toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)
Fatima Ladha, BScPharm, PharmD (Assistant Editor)
Mario de Lemos, PharmD, MSc(Oncol)

Jeevan Dosanjh, RN, BScN
Alina Gerrie, MD, MPH, FRCPC
Alison Pow, BScPharm